Nurix Presents Bexobrutideg Data at ASH
Nurix Therapeutics will present new clinical data on its investigational BTK degrader bexobrutideg at the 68th ASH Annual Meeting in December.
Updated on Nov. 5, 2026 in Cancer
Nurix Therapeutics, a clinical-stage biopharmaceutical company based in Brisbane, California, announced that new and updated clinical data on its investigational oral BTK degrader bexobrutideg (NX-5948) will be presented at the 68th ASH Annual Meeting. The poster presentation is scheduled for December 13, 2026, in New Orleans, Louisiana.
Why it matters
The data focus on patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, including patients previously treated with covalent BTK inhibitors. The presentation offers an early look at how the drug performs in a population with limited remaining options.
Bexobrutideg is administered at a recommended Phase 2 dose of 600 mg once daily, and the ASH poster reports efficacy in patients previously treated with covalent BTK inhibitors. The randomized Phase 3 DAYBreak CLL-306 trial compares bexobrutideg with pirtobrutinib, and outcomes for treatment-naïve patients remain to be disclosed.
The players
Nurix Therapeutics
Nurix Therapeutics is a clinical-stage biopharmaceutical company headquartered in Brisbane, California, developing targeted protein degraders for cancer and other diseases.
Roche
Roche is a Swiss multinational healthcare company and a major pharmaceutical developer that is co-developing bexobrutideg with Nurix.
American Society of Hematology
The American Society of Hematology is a professional organization that hosts the ASH Annual Meeting, one of the largest global conferences on blood disorders.
The details
The data will appear in a poster session titled Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II, session 642, at the 68th ASH Annual Meeting and Exposition. Bexobrutideg is being co-developed by Nurix and Roche.
Timeline
November 5, 2026: ASH released the presentation abstract and Nurix announced the data.
December 12-15, 2026: The 68th ASH Annual Meeting and Exposition takes place in New Orleans.
December 13, 2026: The poster session runs from 6:00 to 8:00 PM in Hall F.
Treatment Landscape
Bexobrutideg is an oral BTK degrader, a different mechanism from covalent BTK inhibitors such as ibrutinib, and this data extends its evaluation into patients previously treated with that drug class. Its planned head-to-head comparison with pirtobrutinib in the DAYBreak CLL-306 Phase 3 trial places it against a non-covalent BTK inhibitor already in use for relapsed disease.
For patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, these data signal a possible oral option after covalent BTK inhibitors, though no approval or availability has been announced. Patients and caregivers in California can track the investigational program through clinical trial listings before the meeting.
The takeaway
Oral degraders may offer a new mechanism for patients whose leukemia has progressed on covalent BTK inhibitors. Readers should watch for the full efficacy and safety results when the ASH data are released.
What happens next
The complete ASH Annual Meeting program and the full set of additional bexobrutideg analyses, including data from BTK inhibitor-naïve and treatment-naïve patients, are expected to be presented at the December 12-15, 2026 meeting in New Orleans.
Further reading
Explore more on Cancer coverage tied to California research and drug development.
More information
Review active studies of bexobrutideg on ClinicalTrials.gov.
Source note: This article includes information reported by The Manila times.
